Cancer Letters
Volume 243, Issue 2 , Pages 145-159 , 18 November 2006

Breast cancer markers

Received 6 December 2005 ,Revised 25 January 2006 ,Accepted 26 January 2006.

References 

  1. Goss PE. The rise and current status of aromatase inhibitors in breast cancer treatment, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 2004;88:S1
  2. Surowiak P, Paluchowski P, Wysocka T, Wojnar A, Zabel M. Steroid receptor status, proliferation and metallothionin expression in primary invasive ductal breast cancer. Pathol. Oncol. Res. 2004;10:207–211
  3. Simpson PT, Reis-Fiho JS, Gale T, Lakhani S. Molecular evolution of breast cancer. J. Pathol. 2005;205:248–254
  4. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia. 1997;2:323–334
  5. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005;24:1434–1444
  6. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65:18–25
  7. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr. Relat. Cancer. 2004;11:391–406
  8. Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution ?. Cancer Treat. Rev. 2005;31:1–17
  9. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle R, Katzenellenbogen BS. Profiling of estrogen up-and down-regulated gene expression in human breast cancers cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003;144:4562–4574
  10. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer. 2004;11:643–658
  11. Serrero G, Dai H, Yue B, Tian C, Tangkeangsirisin W. Neutralization of the autocrine growth factor PCDGF/GP88 by treatment with anti-PCDGF/GP88 monoclonal antibody restores tamoxifen responsiveness in tamoxifen resistant human breast cancer cells, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 2004;88:S33
  12. Massarweh S, Osborne CK, Wakeling AE, Shiff R. Tamoxifen resistence in a breast cancer xenograft model coincides with a switch from a ER+/PgR+ to an ER+/PgR-phenotype accompanied by EGFR/HER2 activation, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S18
  13. Arpino G, Weiss H, Lee A, Schiff R, Osborne CK, Elledge RM. Estrogen receptor positive (ER+), progesterone receptor negative (PgR-) breast cancer: new insights into molecular mechanisms and clinical application, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S21
  14. Turner J, Bentey R, Tao Y, Singh B, Evans DB, Krause A, et al. Changes in tumor grade with neoadjuvant endocrine therapy: morphology evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S37
  15. Schiff R, Osborne CK. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005;7:205–211
  16. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Dan Moore , Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signalling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005;23:1152–1160
  17. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signalling network: receptor heterodimerization in development and cancer. Eur Mol. Biol. Org. J. 2000;19:3159–3167
  18. Stern DF. Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000;176:176–183
  19. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002;62:6770–6778
  20. Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 2005;229:157–169
  21. Arpino G, Weiss H, Wakeling AE, Osborne K, Schiff R. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 2004;88:S15
  22. Arteaga CL, O'Neil A, Moulder SL, Pins M, Sparano JA, Sledge GW, et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib (‘Iressa’) in patients (pts) with HER-2 overexpressing metastatic breast cancer (met br ca), in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S15
  23. Munstermann U, Fritz G, Seitz G, Lu YP, Schneider HR, Issinger OG. Casein kinase II elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J. Biochem. 1990;189:251–257
  24. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene. 2001;20:3247–3257
  25. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear-factor κB in breast cancer. Cancer Res. 2001;61:3810–3818
  26. Cha T-L, Qiu L, Chen C-T, Wen Y, Hung M-C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 2005;65:2287–2295
  27. Zhang L, Lau Y-K, Xia W, Hortobagyi GN, Hung M-C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory of paclitaxel. Clin. Cancer Res. 1999;5:343–353
  28. Zhang L, Chang C-J, Bacus SS, Hung M-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 1995;55:3890–3896
  29. Yang W, Shen J, Wu M, Arsura M, Fitzgerald M, Suldan Z, et al. Repression of transcription of p27 (Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688–1702
  30. Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005;23:1–11
  31. Lo H-W, Xia W, Wei Y, Ali-Seyed M, Huang S-F, Hung M-C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65:338–348
  32. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. Fed. Eur. Biochem. Soc. Lett. 2004;574:1–8
  33. Sgarra R, Tessari MA, Di Bernardo J, Rustighi A, Zago P, Liberatori S, et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics. 2005;5:1494–1506
  34. Diana F, Di Bernardo J, Sgarra R, Tessari MA, Rustighi A, Fusco A, et al. Differential HMGA expression and post-translational modifications in prostatic tumor cells. Int. J. Oncol. 2005;26:515–520
  35. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol. Cell. Biol. 2003;23:9104–9116
  36. Song G, Ouyang G, Bao S. The activation of Akt/PKB signalling pathway and cell survival. J. Cell. Mol. Med. 2005;9:59–71
  37. Nicholson KM, Anderson NG NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002;14:381–395
  38. Nicholson KM, Streuli CH, Anderson NG. Autocrine signalling through erbB receptors promoters constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res. Treat. 2003;81:117–128
  39. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinase and glycogen synthase kinase 3beta. J. Biol. Chem. 2005;280:35195–35202
  40. Farago M, Dominguez I, Landsmann-Bollag E, Xu X, Rosner A, Cardiff RD, et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 2005;65:5792–5801
  41. Le XF, Pruefer F, Bast RC. HER-2 targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathway. Cell Cycle. 2005;4:87–95
  42. Sen P, Mukherjee S, Ray D, Raha S. Involvement of the Akt/PKB signalling pathway with disease processes. Mol. Cell. Biochem. 2003;253:241–246
  43. Kops GJPL, Burgering BMT. Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J. Anat. 2000;197:571–574
  44. West KA, Sianna Castillo S, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 2002;5:234–248
  45. Nicholson RI, Giles MG, Hutcheson IR, Madden T, Gee JMW. Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER− disease. Breast Cancer Online. 2004;7:1–5
  46. Yee D, Sachdev D. Targeting the insulin-like growth factor receptor pathway in breast cancer, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S4
  47. Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistence. Breast Cancer Res. Treat. 2005;93(Suppl. 4):11–18
  48. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 2004;83:249–289
  49. Gee JM, Robetson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer. 2001;95:247–254
  50. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathaway. J. Biol Chem. 2000;275:18447–18453
  51. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. Progression of MCF-7 breast cancer cells to anti-estrogen resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 1996;7:351–359
  52. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumour in vivo. J. Natl Cancer Inst. 2000;29:1926–1934
  53. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation specific antisera. Oncogene. 2002;21:4921–4931
  54. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, et al. Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary glands. Carcinogenesis. 2000;21:871–879
  55. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NF-kappaB subunits in human breast cancer: potential roles for NF-kappa B2/p52 and Bcl-3. Oncogene. 2000;19:1123–1131
  56. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. Her-2 overexpression induces NF-kappaB via a PI3-kinase/Akt Pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene. 2001;20:1287–1299
  57. Chiappetta G, Tallini G, De Blasio MC, Pentimalli F, de Nigris F, Losito S, et al. FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clin. Cancer Res. 2000;6:4300–4306
  58. Battista S, de Nigris F, Fedele M, Chiappetta G, Scala S, Vallone D, et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene. 1998;17:377–385
  59. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, et al. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. Eur Mol. Biol. Org. J. 1997;16:5310–5321
  60. Yang Z, Zhang H, Kumar R. Regulation of E-cadherin. Breast Cancer Online. 2005;8:1–4
  61. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specofic gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64:2024–2029
  62. Sarriò D, Moreno-Bueno G, Hardisson D, Sánchez-Estévez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int. J. Cancer. 2003;106:208–215
  63. Hajra KM, Chen D, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613–1618
  64. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish E, Robertson JFR, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer. 2005;116:340–350
  65. Rakha EA, Armour JAL, Pinder SE, Paish CE, Ellis IO. High-resolution analysis of 16q22.1 in breast carcinoma using amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int. J. Cancer. 2005;114:720–729
  66. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell. Biol. 2003;15:345–350
  67. Butcher DT, Mancini-DiNardo DN, Archer TK, Rodenhiser DI, binding DNA. sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter. Int. J. Cancer. 2004;111:669–678
  68. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of literature. Int. J. Cancer. 2004;112:357–364
  69. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 2003;23:2225–2238
  70. Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, et al. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin. Cancer Res. 2004;10:7637–7644
  71. Hwang ES, McLennan J, Crawford BB, Esserman LJ, Ziegler JL. Incidence and prevalence of ductal carcinoma in situ in BRCA mutation carriers, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 2004;88:S11
  72. Varadhachary A, Wolf JS, Petrak K, O'Malley BW, Spadaro M, Curcio C, et al. Oral lactoferrin nhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer. 2004;111:398–403
  73. Benaïssa M, Peyrat J-P, Hornez L, Mariller C, Mazurier J, Pierce A. Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int. J. Cancer. 2005;114:299–306
  74. Teng CT, Gladwell W, Raphiou I, Liu E. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals. 2004;17:317–323
  75. Miyamoto K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Asahara T, Sugimura T, et al. Identification of 20 genes aberrantly methylated in human breast cancer. Int. J. Cancer. 2005;116:407–414
  76. Stokes K, Alston-Mills B, Teng C. Estrogen response element and the promoter context of the human and mouse lactoferrin genes influence estrogen receptor α-mediated transactivation activity in mammary gland cells. J. Mol. Endocrinol. 2004;33:315–334
  77. Park S-E, Xu J, Frolova A, Liao L, O'Malley BW, Katzenellenbogen BS. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol. Cell. Biol. 2005;25:1989–1999
  78. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J. Cancer. 2005;41:2381–2402
  79. Connor EE, Wood DL, Sonstegard TS, da Mota AF, Bennett GL, Williams JL, et al. Chromosomal mapping and quantitative analysis of estrogen-related receptor alpha-1, estrogen receptors alpha and beta and progesterone receptor in the bovine mammary gland. J. Endocrinol. 2005;185:593–603
  80. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 2005;25:453–472
  81. Tian Q, Zhang J, Chan E, Duan W, Zhou S. Multidrug resistance proteins (MPRs) and implication in drug development. Drug. Dev. Res. 2005;64:1–18
  82. Özvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat. 2005;8:15–26
  83. Filipitis M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, et al. Clinical role of multidrug resistence protein 1 expression in chemotherapy resistence in early-stage breast cancer: the austrian breast and colorectal cancer study group. J. Clin. Oncol. 2005;23:1161–1168
  84. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps. J. 2005;7:E118–E133
  85. Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in the dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci. 2005;96:866–872
  86. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetis, hepatobiliary excretion, and milk secretion of theantibiotic nitrofurantoin. Mol. Pharmacol. 2005;67:1758–1764
  87. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in perpheral blood mononuclear cells and their raletionship with the expression in untestine and liver. Biochem. Pharmacol. 2005;70:949–958
  88. Minisini AM, Di Loreto C, Mansutti M, Artico D, Pizzolitto S, Piga A, et al. Topoisomerase Iiα and APE/ref-1 are associated with pathologic response to primary anthracycline-base chemotherapy for breast cancer. Cancer Lett. 2005;224:133–139
  89. Cui Mao Y, Zhang M, Testell R, Curran EM, Welshons WV, Fuqua SAW. Phosphorylation of estrogen receptor α bloks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004;64:9199–9208
  90. van de Vijver . Gene-expression profiling and the future of adjuvant therapy. Oncologist. 2005;10:30–34
  91. F. Yang, J.A. Foekens, J. Yu, A.M. Sieuwerts, M. Timmermans, J.G. Klijn, D. Atkins, Y. Wang, Y. Jiang, Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes pathways, Oncogene [Epub ahead of print].
  92. Paik S, Kim CY, Song YK, Kim WS. Technology insight: application od molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat. Clin. Pract. Oncol. 2005;2:246–254
  93. del Carmen Garcia Molina Wolgien M, da Silva ID, Villanova FE, Yumi Otsuka A, Borra RC, Lima Reis LF, et al. Differantial gene expression assessed by cDNA microarray analysis in breast cancer tissue under tamoxifen treatment. Eur J. Gyneacol. Oncol. 2005;26:501–504
  94. Glidewell-Kenney C, Weiss J, Lee EJ, Pillai S, Ishikawa T, Ariazi EA, et al. Mol. Cell. Endocrinol. 2005;245:53–59
  95. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl Cancer Inst. 2005;97:1808–1815
  96. Choi D, Kim S, Rimm DL, Carter D, Haffty BG. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005;11:404–411
  97. Chinnaiyan P, Varambally S, Tomlins SA, Ray S, Huang S, Chinnaiyan AM, et al. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer. 2005;(Epub ahead of prints)
  98. Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J. Cancer. 2005;93:1372–1381
  99. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 2005;7:R765–R774
  100. Zhang DH, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomics study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu positive breast cancer. Mol. Cell. Proteomics. 2005;4:1686–1696
  101. Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, Kimmig R, et al. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch. 2005;1–8(Epub ahead of print)
  102. Dobrolecki LE, Sledge GW, Schneider BP, Malkas LH, Hickey RJ. Surface enhanced laser desorption and ionization analysis of serum from patients with metastatic breast cancer prior to undergoing taxane-based therapy, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 2004;88:S50
  103. Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF- MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast. 2005;14:250–255

PII: S0304-3835(06)00078-4

doi: 10.1016/j.canlet.2006.01.035

Cancer Letters
Volume 243, Issue 2 , Pages 145-159 , 18 November 2006

Article Tools

* Image Usage & Resolution